Author: devcuration

There’s pain. Then there’s Sword Health. And the difference is about $3,177 a year, per member. Not in theory, in ROI. In a world full of band-aid solutions and healthtech hype, Sword has built a biomechanical masterpiece that doesn’t just treat the pain, it chokes it out at the root. Founded by Virgílio Bento, a biomedical engineer turned CEO with a PhD in spine-bending problems, Sword started in Portugal with a mission stitched together from clinical grit and code. His co-founder Márcio Colunas brought the algorithmic muscle, crafting motion sensor AI systems that read your movements like a lie detector…

Some medical tech startups are trying to “disrupt” respiratory care. ABM Respiratory Care? They’re actually breathing new life into it. Founded in 2017 out of Singapore by CTO Vinay Joshi and Co-Founder Chad Boerst, ABM started with a pretty wild premise for medtech: what if airway clearance didn’t have to be outdated, invasive, or siloed? What if lung therapy could actually work better, faster, and dare we say, smarter? Fast forward to 2025, and they’ve locked in $14.8M in an oversubscribed Series B round led by healthcare stalwart Peter H. Soderberg, Chairman of the Board and Managing Partner at Worthy…

Zoot just raised $6M to put a new spin on gaming, and this isn’t your cousin’s crypto casino with neon logos and a dream. This is precision-engineered sweepstakes with gaming DNA, blockchain rails, and an executive team that knows how to turn games into empires. Let’s be clear, this isn’t some throwback slots app slapped to a token. Zoot is the first platform I’ve seen that actually gets it: people don’t just want to gamble. They want to play. They want that dopamine hit with the polish of a console, the payoff of a jackpot, and the payment speed of…

Clinical documentation used to be a time-sink with a stethoscope. Now? It’s getting Nabla’d. On June 17, Nabla announced a $70M Series C led by HV Capital, bringing total funding to a cool $120M. But this isn’t just another raise. It’s a full-blown flare from the future of healthcare AI, engineered by founders who’ve lived at the intersection of tech genius and clinical grit. Alexandre Lebrun (CEO), Delphine Groll (COO), and Martin Raison (CTO) didn’t just stumble into this. They built Nabla off real muscle, ex-FAIR, ex-Wit.ai, ex-VirtuOz, and then ran a shadow clinic with 50 doctors to field-test their…

Some folks spend years raising capital just to play dress-up with their pitch decks. Then there’s Extend, legal name CrowdView, Inc., who walked in, parsed the noise, and exited with $17 million across seed and Series A, led by Innovation Endeavors. And they did it without a single hype buffet. This isn’t just another artificial intelligence story dressed in SaaS clothing. Extend is building the infrastructure layer for turning ugly, real-world documents into clean, production-grade data, fast, accurate, and ready to move. It’s like handing your finance, healthcare, or supply chain stack a pair of glasses, then swapping those glasses…

Most startups talk automation like it’s a catchphrase, Celltrio builds it like a surgeon with a robot for a scalpel. And now, they’ve got $15 million to take that precision global. Let’s call it what it is: sterile cell culturing is one of the last holdouts of manual labor in biotech, and that’s not a badge of honor. Celltrio stepped in back in 2018 with a simple thesis and a hell of a toolkit, industrial-grade robotics applied to biopharma’s most finicky workflows. The result? RoboCell, a modular automation platform built to scale sterile cell and gene therapy manufacturing without missing…

For nine years, Diskover played the long game. No spray and pray capital, no sugar high rounds. Just raw execution, heads down engineering, and a product that quietly scaled to organize unstructured data at the kind of volume most platforms can’t even define, let alone index. Now? The stealth is off. Diskover just locked in a $7.5 million Seed round led by Park Capital Partners and The Hive, with heavyweight backup from Snowflake Ventures and NetApp. That’s not your cousin’s angel check. That’s a signal, a green light, a bet on a company with 130+ enterprise customers, a patented architecture,…

In 1981, Cosmo DeNicola didn’t build Amtech Software to chase headlines, he built it to fix the mess no one wanted to touch. Manufacturing floors were still stuck in analog purgatory, lost in paperwork and lag. So DeNicola, an accountant with a taste for precision and a nose for market gaps, coded his way into the chaos. Four decades later, the code evolved, the stakes scaled, and Amtech became the quiet powerhouse moving $13 billion worth of packaging software markets. But “quiet” doesn’t quite cut it anymore. On June 16, 2025, Amtech Software announced a strategic growth investment from Vista…

There’s something that resonates about a company named Other Half going all in. While most startups are trying to dress up filler as function, these two brought lab coats to a dog park and walked out with a $3 million seed round like it was just another Tuesday. AJ Patel doesn’t miss. After building and exiting Zesty Paws for a tidy $610 million and stacking plays with InstaNatural, Zenwise, and HighKey, he could’ve just sat back and surfed exit waves. Instead, he teamed up with Mike Watts, a quiet killer in consumer packaged goods who’s spent 15+ years shaping food…

NeuroEM just cracked open a new chapter in brain tech, and the stakes aren’t just high, they’re cognitive. Picture this: you’re standing in a world obsessed with treating symptoms while the root cause plays Houdini. Now, in walks NeuroEM Therapeutics, Inc., a clinical-stage disruptor out of Tampa with a device that doesn’t just treat Alzheimer’s but dares to reverse its cognitive grip. Yeah, reverse. Not manage. Not delay. Reverse. And the science behind it? That’s not marketing smoke, it’s electromagnetic fire forged in a lab and tested on human minds. Founded in 2013 by Dr. Gary W. Arendash, Ph.D., a…